That process led to the group discovering a lasso peptide that exhibited broad-spectrum antibiotic activity and was effective ...
CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE European Patent ...
Ischemic diseases, such as heart attacks and strokes, occur when blood flow to tissues is disrupted, leading to oxygen ...
The nation's first homegrown electric public transport bus is one of many diverse projects Mexico is supporting in pharma, ...
Chinese biotech start-ups are going up against Western drug makers - and they could win A decade ago, treating cancer with personalised mRNA vaccines seemed like a US$1 million gamble per patient, a ...
RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...
Bioluminescent luciferase enzymes have historically been too dim to use as probes in living tissue. But recent advances have ...
Pfizer (PFE) and other COVID shot makers such as Moderna (MRNA) will face investor scrutiny as FDA's top vaccine regulator Dr ...
RNA is generally single-stranded, as DNA is transcribed by RNA polymerases into mRNA (messenger RNA), which is read by ribosomes to generate protein (translation). Biologically active RNAs ...
("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the European Patent Office ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback